Active	Status	Sponsor type	Region	Phase	Filter
1 Active 0 Inactive 1 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

1 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
CD19-BCMA UCAR-T / Suzhou Maximum Bio-tech
ChiCTR2000039852: To evaluate the safety and tolerability of CD19-BCMA UCAR-T cell injection in patients with relapsed or refractory multiple myeloma	Recruiting	N/A	12		0.5×10^6 UCAR+ T Cells/kg; 1.0×10^6 UCAR+ T Cells/kg; 2.0×10^6 UCAR+ T Cells/kg	Zhongshan People's Hospital; Zhongshan People's Hospital, Suzhou Maximum Bio-tech Co., Ltd.	R/RMultiple myeloma